Freeze-thaw comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
| Property | Value | Notes |
|---|---|---|
| Common separation technique | Reversed-phase HPLC | Separates mainly by hydrophobicity; gradient elution is typical. |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; also detects many organic impurities. |
| Identity confirmation method | LC-MS or MALDI-MS | Provides molecular mass; not a stand-alone quantitative purity measure. |
| Aggregate assessment method | Size-exclusion chromatography | Detects dimers, oligomers, and larger species. |
| Content assessment method | Amino acid analysis | Estimates peptide mass fraction after hydrolysis and separation. |
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
Peptide purity testing distinguishes several impurity classes. Related substances include truncated sequences, deletion peptides, and diastereomers formed during synthesis, while residual solvents, counterions, and water are not peptide-related but affect mass balance. Aggregates and oxidation products can arise during storage. Each class requires different analytical approaches, and a complete purity profile combines separation, mass measurement, and orthogonal assays. Reporting only a single percentage can obscure which impurities are present, so the profile should name the methods and limits used.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
=== Agonists === Non-selective α-MSH β-MSH γ-MSH Afamelanotide Bremelanotide Melanotan II Modimelanotide Setmelanotide MC1-selective BMS-470,539 MC4-selective PF-00446687 PL-6983 THIQ Unknown (but for certain MC2-acting) Alsactide Tetracosactide
Music hall historian Harold Scott wrote that: "..he sang at his piano perched upon a music stool always on the point of collapse, made jokes, gave satirical opinions upon the events of the day and commented unsparingly upon his own prodigious girth; the whole in the breathless manner and rather asthmatical voice, the management of which was the secret of his style." He made several recordings for Odeon Records, including "Limerickitis", and "Suffragettes' Anthem" (not to be confused with "The March of the Women"), in 1910, in which he was "careful to navigate that narrow line between being offensive and being uncontroversial." On the record, he introduces the song by saying that "the remarks [in the song] do not apply to those earnest ladies who are really earnest in their works, but rather the mountebank militants whose extraordinary antics seem to be alienating the sympathies of most right minded people, I refer to the Suffragettes...". The song itself is a parody of Gilbert and Sullivan's "Three Little Maids Are We" and Vesta Victoria's hit "Waiting at the Church": "There was I waiting in the cold, waiting in the cold, chained up in the cold...". In July 1912, Gammon was considered sufficiently respectable to be the opening act (other than a pair of acrobats, Pipifax and Panlo) at the first ever Royal Command Performance for music hall artists, held at the Palace Theatre in front of King George V, Queen Mary and Edward, Prince of Wales. He was a Freemason.
==== Roll-to-roll ==== In 2014, a two-step roll-to-roll manufacturing process was announced. The first roll-to-roll step produces the graphene via chemical vapor deposition. The second step binds the graphene to a substrate.
=== Cardiovascular disease === Recent research suggests that patients with elevated basal levels of CRP are at an increased risk of diabetes, hypertension and cardiovascular disease. A study of over 700 nurses showed that those in the highest quartile of trans fat consumption had blood levels of CRP that were 73% higher than those in the lowest quartile. Although one group of researchers indicated that CRP may be only a moderate risk factor for cardiovascular disease, this study (known as the Reykjavik Study) was found to have some problems for this type of analysis related to the characteristics of the population studied, and there was an extremely long follow-up time, which may have attenuated the association between CRP and future outcomes. Others have shown that CRP can exacerbate ischemic necrosis in a complement-dependent fashion and that CRP inhibition can be a safe and effective therapy for myocardial and cerebral infarcts; this has been demonstrated in animal models and humans. It has been hypothesized that patients with high CRP levels might benefit from use of statins. This is based on the JUPITER trial that found that elevated CRP levels without hyperlipidemia benefited. Statins were selected because they have been proven to reduce levels of CRP. Studies comparing effect of various statins in hs-CRP revealed similar effects of different statins. A subsequent trial however failed to find that CRP was useful for determining statin benefit.
==== Maturation and export ==== The localization of some of the Pvd proteins in the periplasm and the outer membrane (such as PvdN, PvdO, PvdP, and PvdQ) have been interpreted to suggest that portions of the maturation of pyoverdine takes place in this location, perhaps after being transported into the periplasm by PvdE, which is homologous to ABC type exporters. How completely matured pyoverdine is exported from the cell remains unclear. Once completely matured, pyoverdine is exported from the periplasm by PvdRT-OpmQ efflux pump.
Sources: en.wikipedia.org
== Structure == The ITGA1 gene is located on chromosome 5 at cytogenetic band 5q11.2 and spans around 171kb on the positive strand of the human GRCh38 reference genome. The ITGA1 gene encodes the Integrin alpha-1 subunit, a type I transmembrane glycoprotein belonging to the integrin family of cell adhesion receptors. The alpha-1 (α1) Integrin subunit contains an inserted von Willebrand factor type I (I) domain, which mediates the action of binding to collagen. ITGA1 noncovalently associates with the Beta-1 (β1) integrin subunit to form the α1β1 integrin heterodimer, which is a cell-surface receptor also involved in extracellular matrix (ECM) adhesion and signal transduction. The α1β1 integrin receptor is mainly found in the plasma membrane and cell surface, where it is enriched at focal adhesions, which are specialized sites that mediate ECM attachment and intracellular signaling of cells. Gene Ontology annotations also support ITGA1 as a component of the integrin α1β1 complex, which is consistent with its role as an obligate heterodimeric receptor.
==== Acquired ==== Acquired Von Willebrand syndrome can occur due to autoantibodies, either interfering with platelet or collagen binding; increasing VWF clearance from the plasma; adsorption to myeloma cells or platelets; or proteolytic cleavage of VWF after shear stress-induced unfolding. A form of acquired VWD occurs in patients with aortic valve stenosis, leading to gastrointestinal bleeding (Heyde's syndrome). This form of acquired VWD may be more prevalent than is presently thought. In 2003, Vincentelli et al. noted that patients with acquired VWD and aortic stenosis who underwent valve replacement experienced a correction of their hemostatic abnormalities, but that the hemostatic abnormalities can recur after 6 months when the prosthetic valve is a poor match with the patient. Similarly, acquired VWD contributes to the bleeding tendency in people with an implant of a left ventricular assist device (a pump that pumps blood from the left ventricle of the heart into the aorta).
The use of old technologies plays a large factor in how hazardous wastewater results in contaminating the environment. This is especially prominent in small and medium-sized tanneries in developing countries. The UN Leather Working Group (LWG) "provides an environmental audit protocol, designed to assess the facilities of leather manufacturers," for "traceability, energy conservation, [and] responsible management of waste products."
=== Chemistry === Like the other noble gases, krypton is chemically highly unreactive. The rather restricted chemistry of krypton in the +2 oxidation state parallels that of the neighboring element bromine in the +1 oxidation state; due to the scandide contraction it is difficult to oxidize the 4p elements to their group oxidation states. Until the 1960s no noble gas compounds had been synthesized. Following the first successful synthesis of xenon compounds in 1962, synthesis of krypton difluoride (KrF2) was reported in 1963. In the same year, KrF4 was reported by Grosse, et al., but was subsequently shown to be a mistaken identification. Under extreme conditions, krypton reacts with fluorine to form KrF2 according to the following equation:
Around 1500 BCE a tribe called the Oenotri ("vine-cultivators"), settled in the region. Ancient sources state they were Greeks who were led to the region by their king, Oenotrus. However it is more likely they were an ancient Italic people who spoke an Italic language. During the eighth and seventh centuries BCE, Greeks founded many settlements on the coast of southern Italy. In Calabria they founded Chone (Pallagorio), Cosentia (Cosenza), Clampetia (Amantea), Scyllaeum (Scilla), Sybaris (Sibari), Hipponion (Vibo Valentia), Epizephyrian Locris (Locri), Kaulon (Monasterace), Krimisa (Cirò Marina), Kroton (Crotone), Laüs (comune of Santa Maria del Cedro), Medma (Rosarno), Metauros (Gioia Tauro), Petelia (Strongoli), Rhégion (Reggio Calabria), Scylletium (Borgia), Temesa (Campora San Giovanni), Terina (Nocera Terinese), Pandosia (Acri) and Thurii, (Thurio, comune of Corigliano Calabro). In the year 744 BCE a group of Chalcidian settlers founded Rhegion (today Reggio Calabria) at the southern end of the peninsula. Soon after, other Chalcidans founded Zancle (current Messina) on the other side of the strait, securing their dominion over that arm of the sea. Later Chalcidian settlers from Rhegion and Zancle founded Metauros (Gioia Tauro) and divided the river of the same name (today Petrace) from the Italic city of the Tauri. In 710 BCE Ionian colonists founded Sybaris on the fertile plain of the same name at the mouth of the Crati.
Sources: en.wikipedia.org
== Further reading == Underwood, C.R.; Garibay, P.; Knudsen, L.B.; Peters, G.H.; Rudolph, R. & Reedtz-Runge, S. (January 2010). "Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor". J. Biol. Chem. 285 (1): 723–730. doi:10.1074/jbc.M109.033829. PMC 2804221. PMID 19861722.{{cite journal}}: CS1 maint: multiple names: authors list (link) Nielsen, Malene Løvig (18 December 2015). "Pharmaceutical Researcher is New Honorary Professor at Health". AU.dk. Retrieved 13 May 2024. Lotte Bjerre Knudsen from Novo Nordisk is a new honorary professor at Health, Aarhus University. She is the person behind the discovery of liraglutide, a new class of drugs for Novo Nordisk that are used in the treatment of type 2 diabetes and obesity.
== Treatment == Once a nickel allergy is detected, the best treatment is avoidance of nickel-releasing items. The top 13 categories that contain nickel include beauty accessories, eyeglasses, money, cigarettes, clothes, kitchen and household, electronics and office equipment, metal utensils, aliment, jewelry, batteries, orthodontic and dental appliances, and medical equipment. Other than strict avoidance of items that release free nickel, there are other treatment options for reduction of exposure. The first step is to limit friction between skin and metallic items. Susceptible people may try to limit sweating while wearing nickel items, to reduce nickel release and thus decrease chances for developing sensitization or allergy. Another option is to shield electronics, metal devices, and tools with fabric, plastic, or acrylic coverings. There are dimethylglyoxime test kits that can be very helpful to check for nickel release from items prior to purchasing. The American Contact Dermatitis Society 'find a provider' resource can help identify clinicians with training in providing guidance lists of safe items. In addition to avoidance, healthcare providers may prescribe additional creams or medications to help relieve the skin reaction.
The word frankfurter comes from Frankfurt, Germany, where pork sausages similar to hot dogs originated. These sausages, Frankfurter Würstchen, were known since the 13th century and given to the people on the event of imperial coronations, starting with the coronation of Maximilian II, Holy Roman Emperor, as King. "Wiener" refers to Vienna, Austria (German: Wien), home to a sausage made of a mixture of pork and beef. Johann Georg Lahner, an 18th/19th century butcher from the Franconian city of Coburg, is said to have brought the Frankfurter Würstchen to Vienna, where he added beef to the mixture and simply called it Frankfurter. Nowadays, in German-speaking countries, except Austria, hot dog sausages are called Wiener or Wiener Würstchen (Würstchen means "little sausage"), to differentiate them from the original pork-only mixture from Frankfurt. In Swiss German, it is called Wienerli, while in Austria the terms Frankfurter or Frankfurter Würstel are used.
Acetylcysteine or N-acetylcysteine (NAC) is a mucolytic that is used to treat paracetamol (acetaminophen) overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders, such as pneumonia and bronchitis. It has been used to treat lactobezoar in infants. It can be taken intravenously, orally (swallowed by mouth), or by inhalation by use of a nebulizer. It is also sometimes used as a dietary supplement. Common side effects include nausea and vomiting when taken orally. The skin may occasionally become red and itchy with any route of administration. A non-immune type of anaphylaxis may also occur. It appears to be safe in pregnancy. For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralize the toxic breakdown products of paracetamol. When inhaled, it acts as a mucolytic by decreasing the thickness of mucus. Acetylcysteine was initially patented in 1960 and came into medical use in 1968. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
==== Recreational use ==== A 1989 article in the European Journal of Clinical Pharmacology reports that benzodiazepines accounted for 52% of prescription forgeries in Sweden, suggesting that benzodiazepines were a major prescription drug class of abuse. Nitrazepam accounted for 13% of forged prescriptions, and accounted for 44% of forgeries specifically for benzodiazepines while flunitrazepam, diazepam, and oxazepam accounted for the majority of the rest of benzodiazepine forgeries. Prescription forgeries for other benzodiazepines marketed in Sweden (alprazolam, clonazepam, lorazepam, clobazam, and bromazepam) were negligible. When calculated in relation to utilization, the narcotic analgesics codeine, pentazocine, and ketobemidone were at the top of the list for the highest number of overall prescription forgeries, suggesting a higher abuse potential of these drugs. In neighboring Finland, temazepam accounts for roughly 40–50% benzodiazepine prescription forgeries annually, while flunitrazepam accounts for approximately ~15% of benzodiazepine prescription forgeries. Flunitrazepam and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other benzodiazepines and nonbenzodiazepines (anxiolytic or hypnotic) such as zolpidem and zopiclone (as well as cyclopyrrolones, imidazopyridines, and pyrazolopyrimidines) are also found in high numbers of suspected drugged drivers.
Sources: en.wikipedia.org
RP-HPLC purity is the relative area of the main peptide peak compared with the total integrated peak area. It reflects ultraviolet-absorbing species under one set of separation conditions. It does not identify every impurity or measure biological activity.
Chromatographic conditions such as column chemistry, gradient slope, mobile-phase additives, and detection wavelength affect peak resolution. Sample preparation and integration rules also influence area percent values. Without a shared reference standard and validated method, direct comparisons remain uncertain.
Purity describes the proportion of the main peak among detected components. Peptide content measures the amount of the target peptide in a sample after accounting for counterions, water, and residual salts. A sample can have high chromatographic purity but lower net peptide content.
A certificate of analysis reports test results, methods, and specifications for a peptide lot. It often includes appearance, purity by chromatography, mass confirmation, and storage recommendations. It supports quality assessment but does not by itself guarantee suitability for every application.